THE IMPACT OF MEDICAL THERAPY ON BOTHER DUE TO SYMPTOMS, QUALITY OF LIFE AND GLOBAL OUTCOME, AND FACTORS PREDICTING RESPONSE
- 1 October 1998
- journal article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 160 (4) , 1358-1367
- https://doi.org/10.1016/s0022-5347(01)62536-9
Abstract
No abstract availableThis publication has 24 references indexed in Scilit:
- The Effect of Finasteride on the Risk of Acute Urinary Retention and the Need for Surgical Treatment among Men with Benign Prostatic HyperplasiaNew England Journal of Medicine, 1998
- Benign Prostatic Hyperplasia Specific Health Status Measures in Clinical Research: How Much Change in the American Urological Association Symptom Index and the Benign Prostatic Hyperplasia Impact Index is Perceptible to Patients?Published by Wolters Kluwer Health ,1995
- Tamsulosin, a selective α1c‐adrenoceptor* antagonist: a randomized, controlled trial in patients with benign prostatic ‘obstruction’ (symptomatic BPH)British Journal of Urology, 1995
- The Effect of Zanoterone, a Steroidal Androgen Receptor Antagonist, in Men with Benign Prostatic HyperplasiaJournal of Urology, 1995
- Natural History of Prostatism: Relationship Among Symptoms, Prostate Volume and Peak Urinary Flow RateJournal of Urology, 1995
- International Prostate Symptom Score and Quality of Life Assessment Versus Urodynamic Parameters in Men with Benign Prostatic Hyperplasia SymptomsJournal of Urology, 1995
- A three month double‐blind study of doxazosin as treatment for benign prostatic bladder outlet obstructionBritish Journal of Urology, 1994
- Terazosin in the treatment of benign prostatic hyperplasia. Terazosin Benign Prostatic Hyperplasia Study GroupArchives of Family Medicine, 1993
- Finasteride (MK‐906) in the treatment of benign prostatic hyperplasiaThe Prostate, 1993
- The Effect of Finasteride in Men with Benign Prostatic HyperplasiaNew England Journal of Medicine, 1992